Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer
Molecules · 2026
DOI: 10.3390/molecules31030493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Akesh Sinha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Iowa, Iowa City, IA 52242, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Aptamers, Nucleotide, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Congressionally Directed Medical Research Programs, Wake Forest University Health Sciences.
Abstract (Originalsprache)
Prostate cancer is the third-leading cause of cancer death in men. Prostate-specific membrane antigen (PSMA) is a robust biomarker that is expressed in approximately 80% of patients diagnosed with prostate cancer; several theranostic strategies have emerged based upon targeting this biomarker. This report describes a dimeric aptamer complex (DAC) which is selective for PSMA+ cancer cells and is amenable to derivatization with additional diagnostic and therapeutic molecules. Confocal microscopy confirmed the selective nature of the DAC for PSMA+ LNCAP tumor cells. In addition, the affinity of the DAC for the PSMA protein was determined to be 2.16 ± 0.15 nM using biolayer interferometry (BLI). In proof-of-principle studies, this DAC was biotinylated (BioDAC; A10), complexed with streptavidin (SA), and radiolabeled with the positron-emitting radioisotope zirconium-89 (89Zr: t½ = 78.4 h, β+: 22.8%) to form the radiopharmaceutical [89Zr]Zr-Df-SA-BioDAC ([89Zr]Zr-A12). Acute biodistribution studies revealed elevated levels of radioactivity in PSMA+ tumors when compared to PSMA− tumors. Radioactivity retention in the kidney was high due to the presence of streptavidin, while radioactivity retention in the liver was comparable with that of other radiolabeled aptamer complexes. Accordingly, the data suggests that the radiopharmaceutical will need to be redesigned using a strategy that is not reliant on a biotin–streptavidin paradigm before additional preclinical assessments are made and clinical translation can be attempted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Iowa, Iowa City, IA 52242, USA.
- Department of Food Engineering, Adnan Menderes University, Zafer 09100, Turkey.
- Department of Cancer Biology, Wake Forest University Health Sciences, Winston-Salem, NC 27109, USA.
ORCID-Profile: Akesh Sinha, Darpan N Pandya, Prabhakar Eeka, Olcay Boyacioglu, William H Gmeiner, Thaddeus J Wadas
Förderung
- NCI NIH HHS
- Congressionally Directed Medical Research Programs
- Wake Forest University Health Sciences
- Wake Forest Innovations
- North Carolina Biotechnology Center
- University of Iowa
- NCI
- DoD
Zitieren
APA
Sinha, A., Pandya, D. N., Eeka, P., Boyacioglu, O., Gmeiner, W. H., & Wadas, T. J. (2026). Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer. Molecules. https://doi.org/10.3390/molecules31030493
Vancouver
Sinha A, Pandya DN, Eeka P, Boyacioglu O, Gmeiner WH, Wadas TJ. Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer. Molecules. 2026. doi:10.3390/molecules31030493
BibTeX
@article{Sinha2026,
author = {Sinha, Akesh and Pandya, Darpan N and Eeka, Prabhakar and Boyacioglu, Olcay and Gmeiner, William H and Wadas, Thaddeus J},
title = {Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31030493}
}
EUVIMED